Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
KT-621 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
5 August 2026
KT-621: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
HER-2 pulsed DC1(H. Lee Moffitt Cancer Center and Research Institute) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
5 August 2026
HER-2 pulsed DC1(H. Lee Moffitt Cancer Center and Research Institute): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical.
8 min read
MET-2 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
5 August 2026
MET-2: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Alzheimer's disease vaccine(Axon Biochemicals BV) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
5 August 2026
Alzheimer's disease vaccine(Axon Biochemicals BV): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
SMET-12 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
5 August 2026
SMET-12: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Group ACYW135 Meningococcal Conjugate Vaccine (Zhejiang Vacin Biomedicine) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
5 August 2026
Group ACYW135 Meningococcal Conjugate Vaccine (Zhejiang Vacin Biomedicine): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers.
8 min read
VAC-1(Wuchan Zhongda Geron) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
5 August 2026
VAC-1(Wuchan Zhongda Geron): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Danshao Gankang Granules Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
5 August 2026
Danshao Gankang Granules: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Tyroservaltide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
5 August 2026
Tyroservaltide: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
MYL Ointment Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
5 August 2026
MYL Ointment: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Kangminzhenke Granules Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
5 August 2026
Kangminzhenke Granules: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Xiongshao zhitong keli Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
5 August 2026
Xiongshao zhitong keli: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.